Skip to main content
Figure 3 | BMC Clinical Pharmacology

Figure 3

From: No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

Figure 3

Time course of the geometric mean (68% range) plasma concentrations of formoterol (linear scale). Regimen A: Day 18 (roflumilast 500 μg once daily and formoterol 24 μg twice daily at steady state; n = 12); Regimen B: Day 8 (formoterol 24 μg twice daily at steady state; n = 13) and Day 18 (formoterol 24 μg twice daily and roflumilast 500 μg once daily at steady state; n = 12).

Back to article page

BMC Clinical Pharmacology

ISSN: 1472-6904